<?xml version="1.0" encoding="UTF-8"?>
<p class="p">More recently, 
 <italic class="italic">Ginkgo biloba</italic> Extract (GbE) has been investigated as an alternative therapy for metabolic disorders associated with obesity. GbE, a herbal extract containing flavonoids, terpenoids, and terpene lactones (
 <xref rid="B19" ref-type="bibr" class="xref">19</xref>), is a well-known phytotherapic compound often employed as coadjuvant supplement in neurodegenerative diseases (
 <xref rid="B20" ref-type="bibr" class="xref">20</xref>, 
 <xref rid="B21" ref-type="bibr" class="xref">21</xref>), NAFLD (
 <xref rid="B22" ref-type="bibr" class="xref">22</xref>, 
 <xref rid="B23" ref-type="bibr" class="xref">23</xref>), type 1 and 2 diabetes (
 <xref rid="B24" ref-type="bibr" class="xref">24</xref>, 
 <xref rid="B25" ref-type="bibr" class="xref">25</xref>). Previous findings from our research group showed that diet-induced obese (DIO) rats supplemented with GbE showed reduced food and energy intake, reduced body adiposity, improved insulin signalling and sensitivity, enhanced insulin receptor and AKT phosphorylation, and reduced NFÎºB-p65 phosphorylation in retroperitoneal adipose tissue (
 <xref rid="B26" ref-type="bibr" class="xref">26</xref>, 
 <xref rid="B27" ref-type="bibr" class="xref">27</xref>).
</p>
